Vol. 151, No. 26 — December 27, 2017
Registration
SOR/2017-282 December 13, 2017
HUMAN PATHOGENS AND TOXINS ACT
Whereas the Minister of Health is of the opinion that certain micro-organisms, nucleic acids and proteins are able to cause disease in a human and fall into Risk Group 2, 3 or 4 as defined in subsection 3(1) of the Human Pathogens and Toxins Act (see footnote a);
Whereas the Minister of Health is of the opinion that certain micro-organisms, nucleic acids and proteins listed in, or included in those listed in, any of Schedules 2 to 4 to that Act do not fall into the risk group to which the Schedule relates;
And whereas, pursuant to subsection 9(4) of that Act, the Minister of Health has consulted an advisory committee established under subsection 14(1) of the Public Health Agency of Canada Act (see footnote b);
Therefore, the Minister of Health, pursuant to section 9 of the Human Pathogens and Toxins Act (see footnote c), makes the annexed Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act.
Ottawa, December 5, 2017
Ginette Petitpas Taylor
Minister of Health
Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act
Amendments
1 Schedule 2 to the Human Pathogens and Toxins Act (see footnote 1) is amended by deleting the following under the heading “Bacteria”:
- Actinobacillus pleuropneumoniae
- Aerococcus ureinae
- Arcanobacterium bernardiae
- Clostridium difficile
- Francisella novicida
- Salmonella
- Streptococcus salivarius
2 Schedule 2 to the Act is amended by adding the following in alphabetical order under the heading “Bacteria”:
- Aerococcus urinae
- Bacteroides fragilis
- Fusobacterium necrophorum
- Rickettsia akari
- Rickettsia conorii
- Salmonella enterica
3 Schedule 2 to the Act is amended by deleting the following under the heading “Viruses”:
- Adenovirus
- Adénovirus humain
- Avian influenza virus (excluding highly pathogenic strains)
- Virus de la grippe aviaire (sauf les souches hautement pathogènes)
- Coxsackievirus
- Coxsackievirus
- Epstein Barr virus
- Virus d’Epstein Barr
- Hepatitis A virus
- Virus de l’Hépatite A
- Hepatitis D virus
- Virus de l’Hépatite D
- Herpes simplex viruses
- Virus Herpès simplex
- Human coronavirus (excluding SARS-CoV)
- Coronavirus humain (sauf le virus du SRAS)
- Human herpesvirus 5 (cytomegalovirus)
- Herpèsvirus humain de type 5 (cytomegalovirus)
- Human herpesvirus 6 (roseolovirus)
- Herpèsvirus humain de type 6 (roseolovirus)
- Human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus)
- Herpèsvirus humain de type 8 (herpèsvirus associé au sarcome de Kaposi)
- Human parvovirus
- Parvovirus humain
- Human rotavirus
- Rotavirus humain
- Influenza virus, types A-C (excluding Type A 1918 Spanish Flu and H2N2 strains)
- Virus de la grippe (Influenza), types A-C (sauf la souche type A de la grippe espagnole et les souches H2N2)
- Papillomaviruses
- Papillomavirus humain
- Parainfluenza virus (types 1-4)
- Virus Parainfluenza (types 1-4)
- Reoviruses
- Reovirus
- Respiratory syncytial virus
- Virus respiratoire syncytial
- Rhinovirus
- Rhinovirus
- Simian virus 40
- SV40 (Simian virus 40)
4 Schedule 2 to the Act is amended by deleting “Colorado tick fever viruses” under the heading “Viruses”.
5 Schedule 2 to the Act is amended by adding the following in alphabetical order under the heading “Viruses”:
- Alphapapillomavirus
- Alphapapillomavirus
- Hepatitis delta virus
- Virus de l’hépatite delta
- Hepatovirus A
- Hépatovirus A
- Human alphaherpesvirus 1 and 2 (Simplexvirus)
- Alphaherpèsvirus humain de types 1 et 2 (simplexvirus)
- Human betaherpesvirus 5 (Cytomegalovirus)
- Betaherpèsvirus humain de type 5 (cytomégalovirus)
- Human betaherpesvirus 6A, 6B, and 7 (Roseolovirus)
- Betaherpèsvirus humain de types 6A, 6B et 7 (roseolovirus)
- Human gammaherpesvirus 4 (Epstein-Barr virus)
- Gammaherpèsvirus humain de type 4 (Virus d’Epstein-Barr)
- Human gammaherpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus)
- Gammaherpèsvirus humain de type 8 (herpèsvirus associé au sarcome de Kaposi)
- Human parainfluenza virus 1 to 4
- Virus parainfluenza humain de types 1 à 4
- Human respiratory syncytial virus
- Virus respiratoire syncytial humain
- Rhinovirus A to C
- Rhinovirus de type A à C
- Rotavirus A
- Rotavirus A
- Zika virus
- Virus Zika
6 Schedule 2 to the Act is amended by adding the following immediately before “Virus de la fièvre à tiques du Colorado” under the heading “Viruses”:
- Colorado tick fever virus
7 Schedule 2 to the Act is amended by deleting the following under the heading “Fungi”:
- Aspergillus niger
- Aspergillus oryzae
- Sporothrix schenkii
8 Schedule 2 to the Act is amended by adding the following in alphabetical order under the heading “Fungi”:
- Epidermophyton floccosum
- Microsporum canis
- Sporothrix schenckii
- Talaromyces (Penicillium) marneffei
9 Schedule 2 to the Act is amended by adding the following in alphabetical order under the heading “Protozoa”:
- Giardia intestinalis
- Toxoplasma gondii
10 Schedule 2 to the Act is amended by deleting the following under the heading “Prions”:
- Chronic wasting disease agent
- Agent de la maladie du dépérissement chronique des cervidés
11 Schedule 3 to the Act is amended by deleting the following under the heading “Bacteria”:
- Brucella canis
- Brucella ovis
- Brucella suis
- Chlamydia psittaci
- Mycobacterium canettii
- Neorickettsia sennetsu
- Rickettsia akari
- Rickettsia australis
- Rickettsia conorii
- Rickettsia japonicum
- Rickettsia siberica
12 Schedule 3 to the Act is amended by adding the following in alphabetical order under the heading “Bacteria”:
- Chlamydophila psittaci
- Orientia tsutsugamushi
- Rickettsia japonica
13 Schedule 3 to the Act is a mended by deleting the following under the heading “Viruses”:
- African Horse Sickness virus
- Virus de la peste équine
- Água Preta virus
- Virus Agua Preta
- Akabane virus
- Virus Akabane
- Allpahuayo virus
- Virus Allpahuayo
- Andes virus
- Virus Andes
- Araguari virus
- Virus Araguari
- Batken virus
- Virus Batken
- Bayou virus
- Virus du Bayou
- Bear Canyon virus
- Virus du Bear Canyon
- Bermejo virus
- Virus Bermejo
- Bhanja virus
- Virus Bhanja
- Bijou Bridge virus
- Virus Bijou
- Black Creek Canal virus
- Virus Black creek canal
- Cabassou virus
- Virus Cabassou
- Cano Delgadito virus
- Virus Cano Delgadito
- Dhori virus
- Virus Dhori
- Dobrava-Belgrade virus
- Virus Dobrava-Belgrade
- Douglas virus
- Virus Douglas
- Dugbe virus
- Virus Dugbe
- Duvenhage virus
- Virus Duvenhage
- Enseada virus
- Virus Enseada
- Everglades virus
- Virus Everglades
- Flexal virus
- Virus Flexal
- Garissa virus
- Virus Garissa
- Germiston virus
- Virus Germiston
- Hantaan virus
- Virus Hantaan
- Herpesvirus ateles
- Herpèsvirus ateles
- Herpesvirus saimiri
- Herpèsvirus saimiri
- Highly pathogenic avian influenza virus
- Virus de la grippe aviaire (Influenza) hautement pathogène
- Human immunodeficiency virus
- Virus de l’immunodéficience humaine
- Human T-cell lymphotrophic virus
- Virus T lymphotrope humain (HTLV)
- Influenza A H2N2
- Virus de la grippe (Influenza) type A sous-type H2
- Israel Turkey meningoencephalitis virus
- Virus Israel turkey meningoencephalitis
- Issyk-Kul virus
- Virus Issyk Kul
- Juquitiba virus
- Virus Juquitiba
- Khabarovsk virus
- Virus Khabarovsk
- Koutango virus
- Virus Koutango
- Kunjin virus
- Virus Kunjin
- Laguna Negra virus
- Virus Laguna Negra
- Lechiguanas virus
- Virus Lechiguanas
- Lymphocytic choriomeningitis virus
- Virus de la chorioméningite lymphocytaire
- Maporal virus
- Virus Maporal
- Mapuera virus
- Virus Mapuera
- Mayaro virus
- Virus Mayaro
- Mobala virus
- Virus Mobala
- Monongahela virus
- Virus Monongahela
- Mopeia virus
- Virus Mopeia
- Negishi virus
- Virus Negishi
- New York virus
- Virus New York
- Ngari virus
- Virus Ngari
- Oliveros virus
- Virus Oliveros
- O’Nyong-nyong virus
- Virus O’Nyong-nyong
- Oran virus
- Virus Oran
- Oropouche virus
- Virus Oropouche
- Pergamino virus
- Virus Pergamino
- Pirital virus
- Virus Pirital
- Piry virus
- Virus Piry
- Puumala virus
- Virus Puumala
- Rabies virus
- Virus rabique
- Rift Valley fever virus
- Virus de la fièvre de la vallée du Rift
- Rocio virus
- Virus Rocio
- Saaremaa virus
- Virus Saaremaa
- Sakpa virus
- Virus Sakpa
- SARS coronavirus (SARS-CoV)
- Virus du syndrome respiratoire aigu sévère (SRAS-CoV)
- Seoul virus
- Virus Seoul
- Sin nombre virus
- Virus Sin nombre
- Slovakia virus
- Virus Slovakia
- Somone virus
- Virus Somone
- Sripur virus
- Virus Sripur
- Thogoto virus
- Virus Thogoto
- Tonate virus
- Virus Tonate
- Topografov virus
- Virus Topografov
- Vesicular stomatitis virus
- Virus de la stomatite vésiculaire
- Wesselsbron virus
- Virus Wesselsbron
- Whitewater Arroyo virus
- Virus Whitewater Arroyo
- Xingu virus
- Virus Xingu
- Virus Xingu
14 Schedule 3 to the Act is amended by deleting “West Nile fever virus” under the heading “Viruses”.
15 Schedule 3 to the Act is amended by adding the following in alphabetical order under the heading “Viruses”:
- Hantaan orthohantavirus
- Orthohantavirus Hantaan
- Human immunodeficiency virus 1 and 2
- Virus de l’immunodéficience humaine de types 1 et 2
- Lymphocytic choriomeningitis mammarenavirus
- Mammarénavirus de la chorioméningite lymphocytaire
- Rabies lyssavirus
- Lyssavirus rabique
- Severe acute respiratory syndrome-related coronavirus
- Coronavirus du syndrome respiratoire aigu sévère
16 Schedule 3 to the Act is amended by adding the following immediately before “Virus du Nil occidental” under the heading “Viruses”:
- West Nile virus
17 Schedule 3 to the Act is amended by deleting the following under the heading “Fungi”:
- Blastomyces dermatitidis
- Penicillium marneffei
18 Schedule 3 to the Act is amended by adding the following in alphabetical order under the heading “Fungi”:
Blastomyces (Ajellomyces) dermatitidis
Cryptococcus gattii
19 Schedule 3 to the Act is amended by deleting the following under the heading “Prions”:
- Bovine spongiform encephalopathy agent and other related animal transmissible spongiform encephalopathies agents
- Agent de l’encéphalopathie spongiforme bovine et agents des autres encéphalopathies spongiformes transmissibles
- Fatal Familial Insomnia agent
- Agent de la maladie de l’insomnie fatale familiale
- Gerstmann-Sträussler-Scheinker syndrome agent
- Agent du syndrome de Gerstmann-Sträussler-Scheinker
20 Schedule 3 to the Act is amended by adding the following in alphabetical order under the heading “Prions”:
- Bovine spongiform encephalopathy agent
- Agent de l’encéphalopathie spongiforme bovine
21 Schedule 4 to the Act is amended by deleting the following under the heading “Viruses”:
- Absettarov virus
- Virus Absettarov
- Crimean Congo haemorrhagic fever virus
- Virus de la fièvre hémorragique de Congo Crimée
- Guanarito virus
- Virus Guanarito
- Hanzalova virus
- Virus Hanzalova
- Herpes B virus
- Herpèsvirus simien B
- Hypr virus
- Virus Hypr
- Junin virus
- Virus Junin
- Kumlinge virus
- Virus Kumlinge
- Kyasanur Forest virus
- Virus de la forêt Kyasanur
- Lassa fever virus
- Virus de Lassa
- Machupo virus
- Virus Machupo
- Omsk haemorrhagic fever virus
- Virus Omsk
- Russian spring-summer encephalitis virus
- Virus de l’encéphalite verno estivale russe
- Sabia virus
- Virus Sabia
22 Schedule 4 to the Act is amended by deleting “Ebola virus” under the heading “Viruses”.
23 Schedule 4 to the Act is amended by deleting “Marburg virus” under the heading “Viruses”.
24 Schedule 4 to the Act is amended by adding the following in alphabetical order under the heading “Viruses”:
- Crimean-Congo hemorrhagic fever orthonairovirus
- Orthonairovirus de la fièvre hémorragique de Crimée-Congo
- Guanarito mammarenavirus
- Mammarénavirus Guanarito
- Junin mammarenavirus
- Mammarénavirus Junin
- Kyasanur Forest disease virus
- Virus de la maladie de la forêt de Kyasanur
- Lassa mammarenavirus
- Mammarénavirus de Lassa
- Macacine alphaherpesvirus 1
- Macacine alphaherpèsvirus 1
- Machupo mammarenavirus
- Mammarénavirus Machupo
- Omsk hemorrhagic fever virus
- Virus de la fièvre hémorragique d’Omsk
- Sabia mammarenavirus
- Mammarénavirus Sabia
- Tick-borne encephalitis virus
- Virus de l’encéphalite à tiques
25 Schedule 4 to the Act is amended by adding the following immediately before “Virus Ebola” under the heading “Viruses”:
- Ebolavirus
26 Schedule 4 to the Act is amended by adding the following immediately before “Virus Marburg” under the heading “Viruses”:
- Marburgvirus
Coming into Force
27 These Regulations come into force on the day on which they are published in the Canada Gazette, Part II.
REGULATORY IMPACT ANALYSIS STATEMENT
(This statement is not part of the Regulations.)
Issues
The risk grouping and taxonomy of some of the human pathogens listed in Schedules 2 to 4 to the Human Pathogens and Toxins Act (HPTA) require updating to maintain the integrity of the human pathogens and toxins regulatory framework.
Background
The Minister of Health through the Public Health Agency of Canada (PHAC) is responsible for the administration and enforcement of the HPTA and its Regulations, the Human Pathogen and Toxin Regulations (HPTR). The HPTA was enacted in 2009 and came into full force with the HPTR on December 1, 2015. Together, the HPTA and HPTR establish a regulatory framework to protect the health and safety of the public against the risks posed by human pathogens and toxins.
These regulatory amendments are required because Schedules 2 to 4 to the HPTA have not been examined since the enactment of the HPTA in 2009. In light of new scientific information, PHAC reviewed the schedules, in consultation with the Ministerial Advisory Committee on Human Pathogens and Toxins, and determined that some of the taxonomy and risk groupings of the human pathogens on the schedules required updating.
Pursuant to the HPTA, a human pathogen is a micro-organism, nucleic acid or protein that is able to cause disease in a human. In administering the HPTA and HPTR, PHAC classifies human pathogens into four risk groups, based on their risk to human and public health, as follows:
- Risk Group 1 means a category of micro-organisms, nucleic acids, or proteins that are either not capable of causing human disease, or capable of causing human disease, but unlikely to do so. Risk Group 1 organisms capable of causing disease are considered pathogens that pose a low risk to human health, and a low risk to public health. Risk Group 1 pathogens can be opportunistic and may pose a threat to immunocompromised individuals.
- Risk Group 2 means a category of human pathogens that pose a moderate risk to the health of individuals and a low risk to public health and includes the human pathogens listed in Schedule 2. They are able to cause serious disease in a human but are unlikely to do so. Effective treatment and preventive measures are available and the risk of spread of disease caused by those pathogens is low.
- Risk Group 3 means a category of human pathogens that pose a high risk to the health of individuals and a low risk to public health and includes the human pathogens listed in Schedule 3. They are likely to cause serious disease in a human. Effective treatment and preventive measures are usually available and the risk of spread of disease caused by those pathogens is low.
- Risk Group 4 means a category of human pathogens that pose a high risk to the health of individuals and a high risk to public health and includes the human pathogens listed in Schedule 4. They are likely to cause serious disease in a human. Effective treatment and preventive measures are not usually available and the risk of spread of disease caused by those pathogens is high.
The HPTA applies only to those human pathogens falling within Risk Groups 2 to 4, regardless of whether or not they are listed in the schedules to the HPTA. Key representative examples of regulated human pathogens are listed in Schedules 2 to 4, and Part 2 of Schedule 5 to the HPTA. These schedules represent a non-exhaustive list of human pathogens regulated under the HPTA and the HPTR, and serve as a foundational reference point for Risk Group 2 to 4 classifications for both domestic and international stakeholders.
Under the HPTA, the Minister of Health has the authority to add or delete human pathogens from Schedules 2 to 4 by regulation. Prior to making any additions or deletions to the schedules to the HPTA, the Minister is required to consult with an advisory committee. The Ministerial Advisory Committee on Human Pathogens and Toxins was established by PHAC in 2015 to provide scientific advice.
Objectives
The objective of the Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act is to amend the list of human pathogens in the schedules to the HPTA so that they are accurate and up to date, thereby maintaining the integrity of the human pathogens and toxins regulatory regime.
Description
In 2016, PHAC used a human pathogen risk assessment methodology to review Schedules 2 to 4 to the HPTA, in consultation with the Ministerial Advisory Committee, to identify any misclassifications of human pathogens and any errors in nomenclature and taxonomy.
The Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act and the accompanying Regulatory Impact Analysis Statement (RIAS) were prepublished in the Canada Gazette, Part I (CGI) on July 29, 2017, for a 30-day public comment period.
The Agency received 12 sets of comments from three sectors: academia, industry and other federal government departments.
Some commenters provided additional corrections to the taxonomy of listed pathogens. Some commenters requested clarity about the effect of removing pathogens from Schedules 2 to 4 to the HPTA. In addition, due to the procedural requirements of amending statutory changes via regulations, some commenters expressed confusion about how the amended schedules would appear once the HPTA is amended. To reflect the advice of the Ministerial Advisory Committee and address comments received to correct taxonomic errors, the regulatory amendments include additions or deletions of several human pathogens from Schedules 2 to 4. The basis of these changes is outlined in the “Rationale” section.
As stated in the RIAS that accompanied the CGI consultation, the HPTA extends to all human pathogens that fall into Risk Group 2, 3 and 4, regardless of whether or not they are listed on the schedules. There is no requirement for the schedules to include reference to a large number of Risk Group 2 to 4 human pathogens since regulated parties have access to a list of approximately 10 000 human pathogens classified by risk group via the Biosecurity Portal.
To address requests for clarity about how the amended schedules would appear once the HPTA is amended, PHAC has developed a summary of the updated Schedules that will be sent via email to regulated parties.
“One-for-One” Rule
The “One-for-One” Rule does not apply since the Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act do not impose any administrative costs on industry and therefore do not change the Administrative Burden Baseline of the HPTA.
Small business lens
The small business lens does not apply, since Regulations Amending Schedules 2 to 4 to the Human Pathogens and Toxins Act do not impose any administrative burden on small businesses.
Any administrative changes to HPTA licences resulting from the reclassifications reflected in these regulatory amendments will be deferred by PHAC until licence renewal. These amendments will not require regulated parties to change their laboratory procedures.
Rationale
New scientific information led PHAC to review Schedules 2 to 4 to the HPTA, in consultation with the Ministerial Advisory Committee on Human Pathogens and Toxins. Some of the taxonomy and risk groupings of the human pathogens on the schedules require updating.
These regulatory amendments reflect the advice provided by the Ministerial Advisory Committee and the comments received during CGI consultation. The regulatory amendments include additions or deletions of several human pathogens from Schedules 2 to 4 on the following basis:
1. The taxonomy of the human pathogen has changed (e.g. “Virus Hantaan” is changed to “Hantaan orthohanta virus”).
In these cases, the incorrect name was deleted. The new name is either
- added to the appropriate schedule, if the human pathogen is considered to be a representative example for the particular risk group; or
- not added to the schedule because the human pathogen is not considered to be a representative example of the risk group. The human pathogen, however, would continue to be classified under the relevant risk group definition.
2. The human pathogen appears multiple times under different pseudonyms (e.g. the listing of various influenza viruses).
In these cases, the name was deleted.
3. There is insufficient data available about the human pathogen to definitively determine that the human pathogen falls within the definition of the particular risk group classification (e.g. Água Preta virus).
In these cases, the human pathogen was deleted from the schedule, but may continue to be classified under the relevant risk group definition as a precautionary measure.
4. A risk assessment determined that the human pathogen belongs to a different risk grouping. (e.g. Aspergillus niger was reclassified to a Risk Group 1 human pathogen).
In no case did a risk assessment determine that the human pathogen belongs to a higher risk group. In most cases where a human pathogen changed Risk Groupings, the human pathogen was deleted from the higher risk group schedule and added to a lower risk group schedule. In some cases, the human pathogen was removed entirely from the schedules for one of two reasons:
- the human pathogen is considered to be a Risk Group 1 human pathogen; or
- the human pathogen is not considered to be a representative example of the risk group. The human pathogen, however, would continue to be classified under the relevant risk group definition.
As a result of the Regulations:
- ten Risk Group 3 human pathogens were downgraded to Risk Group 2;
- one Risk Group 3 human pathogen was downgraded to Risk Group 1; and
- five Risk Group 2 human pathogens were downgraded to Risk Group 1.
PHAC will allow regulated parties to continue to conduct controlled activities with the reclassified Risk Group 2 human pathogens in the containment zone under their Risk Group 3 licence and will defer any administrative changes to HPTA licences resulting from the reclassifications reflected in these regulatory amendments until licence renewal. Alternatively, regulated parties may transfer reclassified Risk Group 2 human pathogens to a containment zone under a Risk Group 2 licence. These amendments will not require regulated parties to change their laboratory procedures.
The schedules represent key examples of human pathogens regulated under the HPTA and serve as a reference point for risk group classifications to all stakeholders.
The schedules are not required to reference a large number of Risk Group 2 to 4 human pathogens since regulated parties have access to a list of approximately 10,000 human pathogens classified by risk group. This list is currently available to regulated parties via the Biosecurity Portal.
Coordinates
Centre for Biosecurity
Public Health Agency of Canada
100 Colonnade Road, AL: 6201A
Ottawa, Ontario
K1A 0K9
Fax: 613-941-0596
Email: PHAC.pathogens-pathogenes.ASPC@canada.ca
- Footnote a
S.C. 2009, c. 24 - Footnote b
S.C. 2006, c. 5 - Footnote c
S.C. 2009, c. 24 - Footnote 1
S.C. 2009, c. 24